Transaction Details

Footnotes

A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares. The acquisition of 110,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022. | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. | Transaction occurred pursuant to Rule 10B5-1 Plan established August 16, 2024. | The weighted average sales price of the reported transaction was $4.69 based on a range of prices between $4.65 and $4.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. | Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. | Restricted stock unit vested on May 14, 2025, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.